Researchers at University of California San Diego School of Medicine have shown that ustekinumab, a human antibody used to treat arthritis, significantly induces response and remission in patients with moderate to severe Crohn’s disease. Results of the clinical trial will appear in the November 16 issue of the New England Journal of Medicine.

“A high percentage of the patients in the study who had not responded to conventional therapies were in clinical remission after only a single dose of intravenous ustekinumab,” said William J. Sandborn, MD, professor of medicine at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health. … Read the Full Story from the UC San Diego Newsroom

Dr. William Sandborn

William J. Sandborn, MD

William A. Sandborn, MD, is chief of the Division of Gastroenterology in the Department of Medicine.

%d bloggers like this: